MitraClip® therapy in patients with end‐stage systolic heart failure
Top Cited Papers
Open Access
- 1 May 2011
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 13 (5), 569-576
- https://doi.org/10.1093/eurjhf/hfr029
Abstract
Aims To assess the feasibility, short‐term durability and clinical outcomes of MitraClip® therapy for mitral regurgitation (MR) in patients with end‐stage heart failure and a severely reduced left ventricular (LV) ejection fraction. Methods and results We analysed retrospectively collected data from seven European centres. Included in the study were 50 heart failure patients [mean age 70 ± 11 years, 38 men (76%)] with a LV ejection fraction ≤25% and MR of at least grade 3+. All patients had functional MR, were in New York Heart Association (NYHA) functional class III or IV, and their mean logistic EuroSCORE was 34%. The patients underwent a total of 53 MitraClip® procedures; one or more clips were implanted in 50 procedures (48 patients), for an acute procedural success rate of 94%. Severity of MR was reduced in all successfully treated patients, 44 (92%) were discharged with MR ≤2+. Thirty‐day mortality was 6%; cumulative survival at 6 months was 81.2%. Clinical and echocardiographic 6‐month follow‐up data were obtained from 32 and 31 successfully treated patients, respectively. At 6 months, MR ≤2+ was present in 27 (87%) of 31 patients, and 23 (72%) of 32 patients were in NYHA functional class I or II. Six‐minute walk distance improved significantly, and significant reductions in LV volumes indicative of reverse LV remodelling were concordant with significant reductions in N‐terminal pro‐brain natriuretic peptide plasma levels. Conclusion MitraClip® therapy reduces functional MR in patients with end‐stage heart failure and marked LV dysfunction and entails clinical benefit at 6 months.Keywords
This publication has 18 references indexed in Scilit:
- Impact of reduction in early- and late-systolic functional mitral regurgitation on reverse remodelling after cardiac resynchronization therapyEuropean Heart Journal, 2010
- Percutaneous mitral valve repair with the MitraClip system: acute results from a real world settingEuropean Heart Journal, 2010
- Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunctionEuropean Heart Journal, 2010
- Percutaneous Mitral Repair With the MitraClip SystemJournal of the American College of Cardiology, 2009
- 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in AdultsCell Metabolism, 2009
- Quantitative Assessment of Severity of Mitral Regurgitation by Serial Echocardiography in a Multicenter Clinical Trial of Percutaneous Mitral Valve RepairThe American Journal of Cardiology, 2007
- Preoperative left ventricular dimensions predict reverse remodeling following restrictive mitral annuloplasty in ischemic mitral regurgitation☆European Journal of Cardio-Thoracic Surgery, 2005
- Impact of mitral valve annuloplasty on mortality risk in patients with mitral regurgitation and left ventricular systolic dysfunctionJournal of the American College of Cardiology, 2005
- The impact of baseline left ventricular size and mitral regurgitation on reverse left ventricular remodelling in response to carvedilol: size doesn't matterHeart, 2004
- Long-Term Use of a Left Ventricular Assist Device for End-Stage Heart FailureNew England Journal of Medicine, 2001